Abstract:BackgroundAntimalarial drug resistance remains a constant threat, highlighting the need to identify new antimalarials with novel modes of action. Unfortunately, new drug development is often hampered by poor drug-like properties of lead compounds. Prodrugging temporarily masks undesirable compound features, improving bioavailability and target penetration. However, many prodrugs are activated by non-specific host enzymes, losing these beneficial features before they reach their target site. Designing prodrugs that are activated by enzymes specific to a target pathogen, "pathogen specific prodrugs," would allow prodrugs to maintain their beneficial pharmacokinetic and pharmacodynamic effects until they reach their target. We have previously shown that lipophilic ester prodrug modifications substantially increase the potency of antimalarial phosphonates both in vitro and in vivo . However, ester prodrug activation in the malaria parasite, Plasmodium falciparum is poorly understood, as only a single P. falciparum esterase has been characterized.MethodsIn this study, we use a novel fluorogenic ester substrate library, to characterize the substrate specificity of the entire esterase repertoire of P. falciparum . We compare this substrate specificity to that of host erythrocytes, serum, liver and intestinal epithelium. We employ a combination of substrate activity profiling, enzymatic inhibition assays, and liquid chromatography mass spectrometry, to identify the activating enzyme of highly potent antimalarial phosphonate prodrugs.ResultsWe find that structurally similar substrates exhibit varying degrees of activation by human and parasite esterases. We identify a group of long unbranched alkyl substrates that are specifically activated by P. falciparum esterases, suggesting an important structure activity relationship. We also identify an erythrocyte serine hydrolase (APEH), which is imported by the parasite and activates multiple antimalarial phosphonate prodrugs.ConclusionThis study identifies ester prodrug modifications that are specifically activated by P. falciparum , and highlights candidate enzymes responsible for their activation. Our data reveals that an imported human esterase is involved in the activation of antimalarial phosphonate ester prodrugs. Our method can be applied to other organisms or genetic mutants to rapidly characterize esterase activity. Ongoing work will use recombinantly expressed enzymes to specifically characterize their substrate specificities, allowing for the identification of substrates and prodrugs targeted towards those enzymes.

Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action

High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations

Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

Leveraging thePlasmodium falciparum esterase repertoire to design parasite-specific prodrugs

The Cytoplasmic Prolyl-Trna Synthetase of the Malaria Parasite is a Dual-Stage Target of Febrifugine and Its Analogs.

Targeting Plasmodium falciparum IspD in the Methyl-D-Erythritol Phosphate Pathway: Urea-Based Compounds with Nanomolar Potency on target with low micromolar whole-cell activity

In silico screening of selective ATP mimicking inhibitors targeting the Plasmodium falciparum Grp94

Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein

Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition

Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria.

Targeting Plasmodium falciparum IspD in the Methyl-d-erythritol Phosphate Pathway: Urea-Based Compounds with Nanomolar Potency on Target and Low-Micromolar Whole-Cell Activity

Proteomic Profiling of Antimalarial Plasmodione Using 3‐Benz(o)ylmenadione Affinity‐Based Probes

Identification of Potent and Reversible Piperidine Carboxamides That Are Species-Selective Orally Active Proteasome Inhibitors to Treat Malaria

Synthesis and evaluation of fluorinated piperazine‐hydroxyethylamine analogues as potential antiplasmodial candidates

3-Benzylmenadiones and their Heteroaromatic Analogues Target the Apicoplast of Apicomplexa Parasites: Synthesis and Bioimaging Studies

A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo

A non-traditional crystal-based compound screening method targeting the ATP binding site of Plasmodium falciparum GRP78 for identification of novel nucleoside analogues

Identification of novel antiplasmodial compound by hierarquical virtual screening and in vitro assays

Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase

A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1